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http://dx.doi.org/10.1016/j.kjms.201
1607-551X/Copyright ª 2015, KaohsiuAbstract Behc¸et’s syndrome (BS) is associated with chronic inflammation and endothelial
dysfunction. Although there have been extensive investigations on neutrophil-to-lymphocyte
ratio (NLR), platelet-to-lymphocyte ratio (PLR), and mean platelet volume (MPV) in many dis-
eases, their roles in BS is unclear. The purpose of the present study was to evaluate NLR, PLR,
and MPV levels in BS patients and explore their clinical significance. The study included 254
patients with BS and 173 healthy individuals. Age, sex, age of onset, duration of disease, smok-
ing, Behc¸et activity score, total white blood counts, neutrophil, platelet, and T lymphocyte
counts of the patients were recorded. White blood cell (WBC), neutrophil, platelet, NLR,
and PLR were significantly higher in patients with BS when compared with healthy controls
(all p < 0.001). Lymphocyte counts and MPVs of the BS group were not statistically different
from healthy controls (all p > 0.05). In the BS group, PLR and MPV were significantly different
among the three severity groups (pZ 0.037 and pZ 0.016, respectively). We showed that any
laboratory markers were not associated with joint, eye, central nervous system, large vessel,
or gastrointestinal involvement in BS. NLR was shown to be an independent factor for BS by
multivariate analysis. We suggest that NLR can be considered to be a diagnostic criterion of
BS given the support of the findings from larger prospective studies.
Copyright ª 2015, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.eclare no conflicts of interest.
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NLR, PLR and Behc¸et’s syndrome 627IntroductionBehc¸et’s syndrome (BS) is an inflammatory vasculitis char-
acterized by mucocutaneous and joint manifestations,
recurrent thrombophlebitis/thrombosis or deep vein
thrombosis, and eye and central nervous system involve-
ment [1]. BS is classified among vasculitides of unknown
etiology and pathogenesis. BS is associated with chronic
inflammation and endothelial dysfunction [2]. Laboratory
tests are not useful and diagnosis is based upon clinical
manifestations. Blood parameters such as neutrophils and
platelet activities are increased in BS [2,3].
High neutrophil-to-lymphocyte ratio (NLR) and platelet-
to-lymphocyte ratio (PLR) values indicate increased
inflammation [4e7]. NLR and PLR in peripheral blood are
easy systemic inflammatory responses. NLR possesses
diagnostic value in certain pathologies characterized by
systemic or local inflammatory response such as diabetes
mellitus, coronary artery disease, ulcerative colitis, and
inflammatory arthritis [8,9]. PLR is a new biomarker indi-
cating inflammation [10]. PLR is associated with bad prog-
nosis in patients, with a key role in atherosclerosis and
atherothrombosis in peripheral arterial occlusive disease
patients [2]. Furthermore, PLR is thought to be a more
sensitive marker and also assumed to be a prognostic factor
in many malignancies [11]. Mean platelet volume (MPV) is
another marker that shows platelet count and activity. The
MPV has been shown to be associated with inflammation
and inflammation severity [12].
According to the literature, there are only a few studies
examining the relationship between NLR, MPV, and BS. But
there is no study examining the relationship between PLR
and BS. In this study, we aimed to compare the levels of
MPV, NLR, and PLR in patients with BS and healthy controls.
Also, we evaluated the association between disease activity
and MPV, NLR, and PLR as well as other laboratory
parameters.
Methods
Study population
The study was conducted retrospectively in the Derma-
tology and Venereology Department of Akdeniz University,
Antalya, Turkey. The data were extracted from medical
records of patients between January 2014 and December
2014. The study included 254 patients with BS. BS was
based on the criteria of the International Study Group for
Behc¸et’s Syndrome (ICBS) [13]. The study included 173 non-
BS patients diagnosed with pruritus in the dermatology
outpatient clinic. These patients were age- and sex-
matched to the cases. They did not have any dermato-
logic or systemic disorder. First, laboratory test results of
the patients at first diagnosis with BS were recorded during
the examination of the medical records of the patients. The
patients were not taking any medication when the labora-
tory tests were performed. Through making phone calls and
examination of the medical records of the patients, it was
determined that: 52 patients did not take any treatment
because of remission or other causes; 69 patients only used
colchicine; and the remaining 133 patients took single,binary, or triple combined immunosuppressant treatment.
Age, sex, age of onset, duration of disease, follow-up time,
smoking, Behc¸et activity score, total white blood counts,
neutrophil, platelet, T lymphocyte counts, and human
leukocyte antigen (HLA)-B51 positivity of the patients were
recorded.
Patients and control participants who had other skin
diseases, inflammatory or infectious diseases, diabetes
mellitus, or cardiovascular, liver, or kidney diseases were
excluded from the study. Patients with BS who received
colchium, azothiopurin, steroids, and other immune sup-
pressor drugs during the previous 6 months were also
excluded.
Measurements
Total white blood cell (WBC) count, neutrophil, and
lymphocyte differentials were determined using an auto-
mated blood cell counter (Siemens Advia 2120 analyzer,
Erlangen, Germany). Complete blood counts were
measured by the method of laser-based flow cytometric
impedance (BN2 Siemens). Severity score was calculated
as the sum of one point for each of the mild symptoms
(oral aphtosis, genital ulcer, erythema nodosum, pap-
ulopustular lesions, folliculitis, leucocytoclastic vasculitis,
arthralgia, recurrent headaches, epididymitis, chronic
diarrhea, chronic recurrent abdominal pain, colic, pleu-
ritic pain, and superficial vein thrombosis). They received
2 points for each moderate symptom (arthritis, deep vein
thrombosis of the legs, anterior uveitis, and gastrointes-
tinal bleeding), and 3 points for each severe disease
manifestation (posterior/pan uveitis, retinal vasculitis,
arterial thrombosis or aneurysms, major vein thrombosis,
neuro-Behc¸et, and bowel perforation). Categorization of
the severity of the disease was not done according to the
total score. The patient was categorized in the severe
group, even if the patient experienced the severe mani-
festations of the disease once in their lifetime. If there
were no severe findings, whereas one of the moderate
manifestations was detected at a time, the patient was
categorized in the moderate group. Lastly, the patients
who did not have moderate or severe manifestations of the
disease and had BS with only mild manifestations were
considered in the mild group (Figure 1) [14]. Total scoring
was only used in the correlation analysis. Scoring of the
disease and blood sampling were not done simultaneously.
For the blood counts, first blood test results of the patients
when they had been just diagnosed with BS (e.g., 10 year
old hematologic test results of the patient) were consid-
ered. But for the disease severity scale, every symptom/
attack that the patient had experienced throughout his/
her life was taken into consideration. The patients that
were on any drugs during the blood sampling were left out
of the study.
Statistical analysis
Analyses were performed using SPSS software (version 20.0,
SPSS Inc., Chicago, IL, USA). Continuous datawere presented
as mean  standard deviation (SD). Differences in the
continuous variables between groups were determined by
Mild                       Oral aphtosis, 
(each one 1 point) genital ulcer, 
typical skin lesions (erytema nodosum,
papulopustular lesions, folliculitis      
leucocytoclastic vasculitis),
arthralgia, 
recurrent headaches,
epididymitis,
mild gastrointestinal symptoms (chronic diarrhea,
chronic recurrent abdominal pain, colic),
pleuritic pain,
superficial vein thrombosis.
Moderate      Arthritis, 
(each one 2 points)                 deep vein thrombosis of the legs, 
anterior uveitis, 
gastrointestinal bleeding,
Severe             Posterior/pan uveitis,
(each one 3 points) retinal vasculitis,
arterial thrombosis or aneurysm,
large vein (vena cava, hepatic) thrombosis,
neuro-Behçet,
bowel perforation.
Figure1. Krause’s assessment of Behc¸et’s syndrome activity
(Krause, 1999).
Table 1 The demographic and laboratory characteristics
of the patients with Behc¸et’s syndrome and control groups.
Behc¸et’s syndrome
(n Z 254)
Control
(n Z 173)
p
Age (y) 42.83  10.49 41.06  12.31 0.150
Male/female 140/114 99/74 0.667
WBC 8.48  1.72 6.69  1.51 < 0.001
Neutrophil
(103/mL)
5.72  1.74 3.80  1.20 < 0.001
Lymphocyte
(103/mL)
2.01  0.64 2.17  0.91 0.125
Platelet
(103/mL)
287.36  70.89 253.61  67.37 < 0.001
NLR 3.37  2.74 1.95  1.21 < 0.001
PLR 157.69  73.59 127.75  46.02 < 0.001
MPV 8.69  1.03 8.70  0.99 0.305
Data are presented as mean  standard deviation.
MPV Z mean platelet volume; NLR Z neutrophil/lymphocyte
ratio; PLR Z platelet/lymphocyte ratio; WBC Z white blood
cell.
628 S. Alan et al.Student t test or theManneWhitneyU test, for variables with
or without normal distribution, respectively. To test the
normal distribution, the KolmogoroveSmirnov test was used.
Categorical variables were summarized as percentages and
compared with the c2 test. Because all continuous variables
are non-normal, the Spearman correlation coefficient was
computed to examine the association between two contin-
uous variables. Because some variables are non-normal and
some variables are normal the KruskaleWallis test and one
way analysis of variance test were used to compare the three
severity groups. Logistic regression analysis was also con-
ducted to assess relationships; results are presented as odds
ratios (OR) and 95% confidence intervals. Input variables ofbinary logistic regression were NLR, PLR, and sex. Statistical
significance was defined as p < 0.05.
Results
Our study sample comprised 254 patients with BS and 173
healthy controls. Age and sex were similar between the
groups. The comparisons among the healthy and patients
groups of demographic features and laboratory findings are
shown in Table 1. WBC, neutrophil, platelet, NLR, and PLR
were statistically significant in patients with BS when
compared with healthy controls (all p < 0.001; Table 1).
One hundred and twenty of them were in the mild group, 66
of them in the moderate group and 68 of them were in the
severe group. In the BS group, PLR and MPV were signifi-
cantly different among the three severity groups.
(p Z 0.037 and p Z 0.016, respectively; Table 2). There
were no statistically significant differences between PLR
and MPV of the severe and moderate groups and the mod-
erate and mild groups. PLR and MPV of the severe group
were significantly higher than the PLR and MPV of the mild
group (p Z 0.032, p Z 0.015, respectively; independent-
samples ManneWhitney U test). Otherwise we showed
that NLR, PLR, and MPV were not associated with joint,
eye, central nervous system, large vessel, or gastrointes-
tinal involvement in BS (p ˃ 0.05; Table 3). According to
Krause’s scoring system, the mean severity scores of the
patients with BS were detected as 5.28  0.13. There were
no correlation between the severity score of BS and the
laboratory parameters (p ˃ 0.05). Multivariate analysis
found that NLR was an independent predictor for BS
(p < 0.001, OR Z 2.535; Table 4).
Discussion
The marked findings of the present study were that NLR,
PLR, WBC, neutrophils, and platelets were different in the
Table 2 Demographic and clinical characteristics of different severity groups in patients with Behc¸et’s syndrome.
Mild disease (n Z 120) Moderate disease (n Z 66) Severe disease (n Z 68) p
Age (y) 42.90  9.94 44.62  12.27 40.99  9.30 0.689
Male/female 57/63 36/30 47/21 0.016
Follow up time (y) 5.51  3.38 6.68  3.32 6.13  3.59 0.067
Duration of disease (y) 6.94  5.92 8.91  5.99 8.51  5.81 0.006
Family history (þ) 18/102 10/56 8/60 0.801
Current smokers 19/101 14/52 44/24 < 0.001
HLA B51 (þ) 20/100 21/45 34/34 < 0.001
Hematuria (þ) 19/101 10/56 16/52 0.339
Proteinuria (þ) 9/111 3/63 6/62 NAa
WBC 8.45  1.68 8.38  1.67 8.63  2.33 0.590
Neutrophils (103/mL) 5.65  1.64 5.64  1.89 5.92  0.21 0.051
Lymphocytes (103/mL) 2.06  0.54 2.00  0.63 1.99  0.68 0.080
Platelets (103/mL) 287.34  68.65 281.66  62.65 292.94  82.06 0.205
NLR 3.03  1.07 3.50  1.12 3.82  1.41 0.150
PLR 150.28  71.74 156.61  69.23 171.82  79.75 0.037
MPV 8.59  0.96 8.61  1.10 8.92  0.13 0.016
Data are presented as mean  standard deviation.
MPV Z mean platelet volume; NA Z not applicable; NLR Z neutrophil/lymphocyte ratio; PLR Z platelet/lymphocyte ratio;
WBC Z white blood cell.
a Two cells (33.3%) have an expected count< 5. The minimum expected count is 4.68.
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MPV were significantly higher in patients with severe BS
compared with mild BS. We showed that NLR was an asso-
ciated factor for the presence of BS.
Some studies claimed that NLR is a new biomarker which
indicates the presence of inflammation in literature.
Various studies have demonstrated the correlation between
NLR and the severity of some systemic inflammatory dis-
eases as well as coronary artery disease [4]. In theTable 3 Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyt
system involvements.
NL
Joint involvement þ 3.30 
 3.48 
p 0.205
Eye involvement þ 3.81 
 3.11 
p 0.241
CNS involvement þ 3.69 
 3.35 
p 0.250
GIS involvement þ 3.49 
 3.36 
p 0.454
Arterial/venous involvement þ 2.73 
 3.37 
p 0.750
Thrombo phlebitis þ 3.44 
 3.36 
p 0.165
Data are presented as mean  standard deviation.
CNS Z central nervous system; GIS Z gastrointestinal system; MPV
PLR Z platelet/lymphocyte ratio.literature, Balta et al. [15] showed that the NLR, C-reactive
protein (CRP), and the WBC levels were higher in patients
with BS than controls. In addition, NLR was higher in pa-
tients with active BS than in those with inactive BS. O¨ztu¨rk
et al. [16] investigated the correlation between NLR and
inflammatory activity in BS. They showed that NLR levels
were significantly higher in active patients with BS than in
inactive patients. Similarly, different studies demonstrated
NLR as a useful marker for indicating the presence ande ratio, and mean platelet volume values in cases of different
R PLR MPV
2.82 155.34  66.91 8.62  0.99
2.62 161.28  84.06 8.81  1.10
0.646 0.250
3.70 166.27  83.11 8.79  1.06
1.97 152.60  67.23 8.63  1.02
0.225 0.078
2.01 155.40  45.85 8.57  1.45
2.76 157.78  74.57 8.69  1.02
0.537 0.765
1.53 165.16  59.64 8.75  1.16
2.76 157.51  73.99 8.69  1.03
0.621 0.518
1.86 100.73  40.98 8.75  1.34
2.75 158.02  73.79 8.69  1.04
0.153 0.911
1.52 153.39  52.74 8.75  1.23
2.85 158.03  73.75 8.68  1.03
0.751 0.591
Z mean platelet volume; NLR Z neutrophil/lymphocyte ratio;
Table 4 Binary forward stepwise logistic regression
analysis of variables related to Behc¸et’s Syndrome.
95% CI
p OR Lower Upper Nagelkerk
R2
Coxe
Snell R2
NLR <0.001 2.535 1.878 3.301
PLR 0.323 0.998 0.992 1.003
MPV 0.315 0.898 0.729 1.109 0.219 0.162
CI Z confidence interval; MPV Z mean platelet volume;
NLR Z neutrophil/lymphocyte ratio; OR Z odds ratio;
PLR Z platelet/lymphocyte ratio.
630 S. Alan et al.prognosis of inflammatory diseases and malignancies [8,18].
Also in our study, only NLR was detected as an independent
decisive factor among the laboratory parameters in BS ac-
cording to the multivariate analysis. Based on this data, we
believe that NLR can be a useful laboratory parameter in
the diagnosis of BS. Similarly to the literature, we found
that the mean NLR values of the patient group were
significantly higher than the mean NLR values of the control
group.
PLR is a novel biomarker which can demonstrate the
presence and severity of inflammation [10]. Kokcu et al.
[17] reported that the NLR, platelet count, and the PLR
increased with the increasing stage of ovarian cancer. Also,
they claimed that the PLR was an independent prognostic
factor related to the stage of epithelial ovarian cancer.
Racz et al. [18] showed that high PLR was associated with
reduced recurrence-free survival in patients with gastro-
intestinal stromal tumors. Similarly, Azab et al. [7] reported
the presence of a correlation between increased PLR and
long-term mortality in patients presented with non-ST
segment elevation myocardial infarction. In another
study, increased PLRs were found to be associated with
non-dipper state in hypertensive patients [19]. This is the
first study that showed the association between PLR and a
novel marker of the presence and severity of BS.
MPV has been widely used as a new marker of inflam-
mation. Ekiz et al. [20] showed that the patients with BS
and recurrent aphtous stomatitis had significantly higher
MPV and erythrocyte sedimentation rate levels compared
with controls. Similarly, Yazici et al. [21] found that MPV
was significantly higher in patients with ankylosing spon-
dyloarthritis and rheumatoid arthritis, and MPV reflected
the activity of both diseases. Nevertheless, we did not find
a significant difference in MPV levels among the patients
with BS and healthy controls. Kisacik et al. [22] showed that
high grade inflammation was associated with a decrease in
MPV levels in the other chronic inflammatory diseases such
as rheumatoid arthritis and ankylosing spondyloarthritis.
Similar to this study, Ac¸ıkgo¨z et al. [23] demonstrated that
any difference between MPV levels and disease activity was
not found. On the contrary, we found a significant differ-
ence in MPV levels of different BS severity groups. Platelets
are essential in hemostasis and the formation of both
arterial [24] and venous thrombosis [25]. Platelet count is
also a marker of host systemic inflammation [10]. The
platelet count can be determined by both inherited and
environmental factors [26]. In different studies, abnormalincreases in platelet counts have been associated with the
development of atherosclerosis, atherosclerotic heart dis-
ease, and major cardiovascular events [27]. Jensvoll et al.
[28] claimed that precancer platelet count was associated
with risk of symptomatic venous thromboembolism in can-
cer patients, but not in cancer-free individuals. Also, they
showed that the combination of platelet and leukocyte
counts in the upper quintiles had a synergistic effect and
yielded a threefold increased risk of venous
thromboembolism.
Neutrophils are actively involved in systemic and local
inflammatory responses by releasing proinflammatory ele-
ments [9]. Significant roles of leukocytes and particularly
neutrophils in atherogenesis and atherothrombosis are
already recognized [29]. Neutrophils are the main agents
responsible for tissue damage and have an intrinsic hyper-
activation in BS patients [29]. Our study demonstrates that
the platelet, neutrophil, and leukocyte counts are higher in
patients with BS compared to healthy controls. Otherwise,
we found that leukocyte and platelet counts were not
associated with venous and arterial thrombosis or other
systems involvement.
There are some limitations of our study. First, this is a
retrospective study. Because this study was not a cohort
study, the findings did not offer convincing evidence to
demonstrate that PLR and MPV might be helpful as a
biomarker to “predict” the severity of BS. Second, we used
spot NLR, PLR, and MPV values for our analysis, rather than
follow-up values. Because this study was retrospective, we
couldn’t use Behc¸et’s Syndrome Current Activity Form
(BSCAF) for assessing disease activity. Third, we did not
perform an analysis of the prognostic value of NLR, PLR,
and MPV in BS.
In light of our findings, NLR and PLR might be associated
with the presence and severity of BS. We suggest that NLR
can be considered to be a diagnostic criterion of Behc¸et’s
syndrome given the support of the findings from larger
prospective studies.References
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